Pharmaceutical Technology on MSN4d
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
MPR2d
Tevimbra Plus Chemotherapy Approved as First-Line Tx for Advanced Esophageal Cancer
The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...
CURE5d
FDA Approves Tevimbra Plus Chemotherapy For Some With Esophageal Cancer
The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma ...
BeiGene wins FDA nod for Tevimbra in first-line esophageal cancer
BeiGene (NASDAQ:ONC) announced Tuesday that the U.S. Food and Drug Administration (FDA) approved its anti-tumor agent ...
BioSpace5d
BeiGene Gets Yet Another Label Expansion for PD-1 Drug Tevimbra
The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...
Managed Healthcare Executive4d
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...
PMLive4d
BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use
BeiGene’s Tevimbra (tislelizumab-jsgr) has been approved by the US Food and Drug Administration (FDA) as part of a first-line ...
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively. Check out why I rate ONC stock as a Buy.
Medscape4d
Tislelizumab Receives First-Line Nod for Unresectable/Metastatic ESCC
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...
Yahoo Finance4d
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing chemotherapy as first-line treatment for adults with unresectable or ...